Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of recombinant quadrivalent HPV vaccine in healthy Chinese women aged 18-45 years
ChiCTR1800016432Phase 3Recruiting
- Sponsor
- Hunan Center for Disease Control and Prevention
- Start
- Mar 2018
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle in human papillomavirus infection and Cervical Cancer (CC) (2 arms), sponsored by Hunan Center for Disease Control and Prevention. Primary endpoints: 12-month persistent infection associated with HPV types 6, 11, 16, and 18 and Prevention of HPV 6/11/16/18 type-specific CIN2+ lesions. Started Mar 2018; status: recruiting.
02
Drugs
quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle
03
Conditions
human papillomavirus infectionCervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR1800016432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016432.